Key Points
- Insider Melissa Mclaughlin sold 1,624 shares on April 2 for about $519,014, and additionally sold 2,286 shares on April 6 for about $755,340, reducing her position to 11,729 shares (a 12.16% decrease).
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan and were made to cover tax withholding obligations related to the vesting of equity awards.
- Alnylam recently missed quarterly EPS and revenue estimates despite revenue rising 84.9% year-over-year, and analysts maintain a consensus rating of "Moderate Buy" with an average price target of $473.87.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) insider Melissa Mclaughlin sold 1,624 shares of the business's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $319.59, for a total value of $519,014.16. Following the sale, the insider directly owned 11,729 shares of the company's stock, valued at approximately $3,748,471.11. This trade represents a 12.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Melissa Mclaughlin also recently made the following trade(s):
- On Monday, April 6th, Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $330.42, for a total value of $755,340.12.
Alnylam Pharmaceuticals Price Performance
ALNY stock opened at $319.52 on Wednesday. The stock has a 50-day moving average price of $325.44 and a two-hundred day moving average price of $392.98. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company has a market cap of $42.38 billion, a PE ratio of 186.85 and a beta of 0.39.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The firm had revenue of $1.10 billion for the quarter, compared to analysts' expectations of $1.16 billion. During the same period last year, the firm posted ($0.65) EPS. Alnylam Pharmaceuticals's revenue was up 84.9% on a year-over-year basis. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on ALNY shares. Stifel Nicolaus upped their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a "buy" rating in a research report on Thursday, December 11th. Wall Street Zen downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, March 21st. Freedom Capital raised Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 17th. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a "buy" rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings downgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $473.87.
View Our Latest Report on ALNY
Institutional Investors Weigh In On Alnylam Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. Root Financial Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $25,000. Salomon & Ludwin LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $27,000. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Finally, HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. Hedge funds and other institutional investors own 92.97% of the company's stock.
Alnylam Pharmaceuticals Company Profile
(
Get Free Report)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
